BioPharma Dive November 13, 2024
Gwendolyn Wu

The California biotech, which is partnered with Eli Lilly and J&J, plans to use the funds to advance one of its wholly owned drugs for eczema into Phase 1 testing.

Dive Brief:

  • TRex Bio, a California biotechnology company that’s partnered with Eli Lilly and Johnson & Johnson, has raised $84 million in a Series B round meant to advance its immune drug research, the company said Wednesday.
  • The new funds will be used to push the company’s second drug candidate, dubbed TRB-061, into a Phase 1 clinical trial in the first half of next year. The drug is designed to treat atopic dermatitis and ulcerative colitis.
  • The round adds to two milestone payments TRex earned earlier this year from...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Investments, Pharma / Biotech, Trends
Related Articles:
Bristol Myers Squibb says Alzheimer's is the biggest market for new schizophrenia drug
At JPM, Eli Lilly’s CEO Explains Why Mounjaro, Zepbound Sales Were Lower Than Expected
NIH's unfinished business
Lilly blames slower-than-expected growth for 2024 sales miss
AbbVie to write off $3.5B over failed schizophrenia drug

Share This Article